SiVEC Biotechnologies

SiVEC Biotechnologies is a private, preclinical-stage biotech company pioneering a bacterial-based drug delivery platform. Its core technology, BactPac™, uses engineered bacteria to produce and deliver therapeutic payloads directly to target tissues, aiming to overcome limitations of viral vectors and lipid nanoparticles. The company is advancing an internal pipeline led by SVC-KRAb™, a pan-RAS cancer therapeutic, while also seeking partnerships with pharmaceutical companies to deploy its platform for next-generation nucleic acid and gene therapies. SiVEC represents a novel approach in the targeted delivery space, with potential applications across multiple high-need therapeutic areas.

BactPac™ is a live biotherapeutic delivery platform that uses engineered bacteria to produce and deliver therapeutic payloads (mRNA, siRNA, proteins/nanobodies, CRISPR/Cas) to targeted tissues, aiming to overcome limitations of viral vectors and lipid nanoparticles.

SiVEC competes with other next-generation delivery companies developing LNPs, viral vectors, and alternative bacterial systems. In oncology, it faces direct competition from numerous biopharma companies developing small molecule and biologic RAS inhibitors, including Revolution Medicines (RMC-6236).